|
New medicine offers another defense in the asthma war
Allentown Morning Call The U.S. Food and Drug Administration this week gave marketing approval to GlaxoSmithKline's Arnuity Ellipta, an inhaled corticosteroid medicine designed to be taken a once a day by asthma patients 12 years of age and older. It's not for someone having … |
View full post on asthma – Google News